HEALTH TECHNOLOGY

REVIV Releases game-changing COVID-19 management software

REVIV | December 14, 2020

Because of worries over the Government's contact tracing framework and the struggling organizations in the UK, Sarah Lomas, the President and CEO of REVIV, devoted the organization's endeavors to give an answer to the UK as well as across the world. In a joint effort with a bleeding edge advancement group, driven by tech master Idan Udi Edry, REVIV has made HELIIX - the most strong and successful management programming presently available.

 

REVIV, the world-driving organization in precaution wellbeing, is dispatching a COVID-19 management answer for organizations. The pandemic hit and REVIV responded to bring a not-for-benefit helpline worked by their master clinical experts, not-revenue driven PCR and immunizer testing at a straightforward and top notch cost of £89. Also, presently they're pleased to dispatch HELIIX an imaginative COVID-19 danger profiling and management framework to get representatives back in the work place securely.

 

The turn out of the invited immunization started a week ago yet it very well may be a long time before the UK's overall labor force may get it. HELIIX is the ideal arrangement while we are as yet doing combating the Covid.

 

REVIV is most popular in the UK for their IV and promoter shot treatments and far reaching hereditary testing. Presently HELIIX is offering organizations shrewd danger profiling, powerful following and case management, debilitated compensation anticipating, client disconnection cautions thus significantly more inside the product framework - all workers need to do is download and update the app on their telephone for continuous functionality.

 

Non-Executive Board Director Max Johnson says: "All employers need a COVID-19 management software to make their companies run smoothly and safely. We think HELIIX is just the software to enable them to do that."

 

Professional functionality of HELIIX is charged at just £1.40 per user a month. All subscriptions are free to cancel at any time.

 

Sarah was recently on the popular BBC documentary, Manctopia: Billion Pound Property Boom. She shared her story of growing up poor in Manchester and returning years later to establish the HQ of a global health and wellness company worth £100m. Sarah also recently spoke to Business Live about the discrimination she faced over her northern accent during her banking career, which led her to leave the country to work abroad only returning to set up the REVIV HQ.

Spotlight

Healthcare’s "new front door" is the first stop on a consumer’s care journey. Banging this door down means vying for a different kind of consumer relationship. This relationship starts well before the consumer’s initial primary care or doctor visit. It begins with the tools that support consumers’ decision-making on whether and where to seek care. For this series, we take this “new front door” definition a step further and consider the strategic control and care delivery pieces connected right after someone steps through this door. This stage is what foreshadows the dynamics the new doors will drive in influencing consumer care patterns.


Other News
MEDICAL DEVICES

CeloNova Announces New Strategic Direction Focused on Creating Partnership

CeloNova BioSciences, Inc. | April 08, 2022

CeloNova BioSciences, Inc. developer and manufacturer of a portfolio of novel surfaced coated technologies, including the proprietary Polyzene™-F nanocoating, announced the strategic decision to focus its core business on creating partnership and co-development opportunities with medical device manufacturers seeking to optimize implant interaction within the body. The company's nanocoated innovation is the result of years of rigorous scientific research and engineering and has been extensively published in numerous academic articles to date. "We are pleased to offer leading medical device manufacturers access to the unique clinical advantages of our Polyzene-F nanocoated technology that has clinically demonstrated low thrombosis, restenosis and inflammation with rapid healing effects," stated Carl St. Bernard, President and Chief Executive Officer of CeloNova. "This technology offers a significant benefit to companies seeking to improve the clinical performance of their implant technologies." "I fully support CeloNova's new strategic direction which allows medical device manufacturers to benefit from long-term biocompatibility and thromboresistance of Polyzene-F. When my students and I set out to study the hemocompatibility of this inorganic polymer in our lab in Heidelberg Germany, we soon realized its potential to significantly limit a wide range of implant complications and being broadly applied in the human body and in biomedical devices." Professor Dr. Michael Grunze, Former Chair and Professor (emeritus) at the Institute of Applied Physical Chemistry of the Ruprecht-Karls-University in Heidelberg and co-inventor of Polyzene-F CeloNova is based on a rich history of medical innovation with two PzF coated medical implants successfully commercialized in the U.S. and the EU. The company's PzF coated embolic microspheres product line was sold to Boston Scientific in 2015 and the COBRA PzF NanoCoated Coronary Stent, was developed to safely and effectively treat patients who may benefit from 1-month of dual antiplatelet therapy. CeloNova's new business direction builds upon the successful application of PzF in interventional oncology and cardiology and expands its opportunities through the development of new surface coating technologies to address important unmet clinical needs. "In my pre-clinical research at CVPath since 2012, CeloNova's proprietary Polyzene-F coating has consistently demonstrated a unique advantage of allowing an implant to heal quickly and in a functional way, without the need for antiproliferative drug elution," stated Aloke Finn, MD, Medical Director and Chief Scientific Officer at CVPath and Associate Professor of Medicine at the University of Maryland. "I believe Polyzene-F will continue to play an important role in delivering safety and efficacy in clinical practice." Polyzene-F is a proprietary, ultra-pure and highly elastic surface coating possessing unique mechanical properties that allow an implant to be coated at a nanoscale level. The coating acts as a biocompatible barrier between the implant, intimal surface and circulating elements in the blood and has demonstrated thromboresistant and anti-inflammatory properties with significantly faster, higher quality healing compared to market-leading technologies.1* About CeloNova BioSciences, Inc. CeloNova BioSciences, Inc. is a global medical device company that develops, manufactures and markets novel surfaced coated technologies, including its proprietary Polyzene™-F nanocoating. The next generation nanocoating is the result of years of rigorous scientific research and engineering and has been extensively published in numerous academic articles to date.

Read More

FUTURE OF HEALTHCARE

Mental Health Provider Meru Health collaborates with Tech-Savvy Health Insurance Company Evry Health To Deliver Outcomes-Based Mental Healthcare

MERU HEALTH | January 18, 2022

Meru Health, the most comprehensive mental health solution in the market with industry-leading outcomes, and Evry Health, a modern business-to-business health insurance company announced today that they will partner on delivering Meru Health's solution to Evry Health's members in Dallas, Texas starting January 2022. The Meru Health online mental health solution will be embedded as part of Evry Health's tailored wellness plans that come at no cost to the employer or their employees. These specialized, optional wellness solutions provide a wide range of resources, tools and rewards that are different from other health insurance plans, including benefits such as mental health support through Meru Health. Members will be recommended to the program based on pre-screening criteria as well as Evry Health's data analysis. For example, if Evry Health receives a claim for cancer screening and oncologist claims, this is a flag to proactively loop the member into Meru Health's mental health program and support cycles. The partnership will focus on delivering outcomes-based mental healthcare and it rewards members for following their personalized care pathways. A member who completes Meru Health's 12-week Therapy program can get up to $100 reward for doing so. "This is a completely new way of delivering mental healthcare and we are proud to partner with Meru Health to together change how the system works," said Chris Gay, Evry Health CEO. "Focusing on outcomes is the way mental healthcare – and healthcare in general – should be delivered now and in the future. We are confident our members will get the best possible value-based care, and see their mental health improve as they go through the Meru Health program." Incentivizing members to take care of their mental health can lead to major cost savings down the line. According to data from BCBS, people with major depression are on average nearly 30 percent less healthy than those without depression. This decrease in overall health translates into increased costs: a depressed person has $6,390 more healthcare costs than nondepressed people every year. Evry Health incentivizes participants to focus on better mental health through its voluntary wellness plans. Rewards are deposited to an Evry Health Reward Card that members use like any other credit card. Meru Health is focused on delivering the best long- and short-term outcomes in the market. After program completion, 75% of people are in depression or anxiety symptom remission and 85% of people show clinically significant improvement, measured on industry standard PHQ-9 (depression) and GAD-7 (anxiety) scales. The Meru Health Program is one of only digital mental health interventions with published research that shows that these treatment gains last 12 months after the end of treatment. "We could not be more excited to partner Evry Health, who is changing health insurance just like we are transforming mental healthcare. Together we can really deliver patient-centric care that ensures that people prioritize their mental health. Health plans and employers would benefit a lot focusing more on outcomes. The question we should be asking is are people getting better and staying better after the treatment? I believe trailblazers like Evry Health will be a role model in the industry to start focusing more on care outcomes." Kristian Ranta, the CEO of Meru Health About Meru Health Meru Health is setting the new standard in mental healthcare with the most comprehensive online solution that combines licensed therapists and psychiatrists, a smartphone-based treatment program, biofeedback training, anonymous peer support, and habit-changing activities for sleep, nutrition, and more. The company is committed to evidence-based care and has published groundbreaking clinical outcomes with Stanford, Harvard, and UC Davis that show promising clinical effectiveness and lasting results. Meru Health offers a convenient, accessible, side-effect-free mental health treatment option in contrast to the standard of care in the U.S. today. Meru Health partners with major health insurance providers like Cigna, Humana, and Moda Health, as well as leading businesses that want to provide best-in-class mental health care for their employees or members. About Evry Health Headquartered in Dallas, Evry Health is not your standard health plan. We're on a mission to make healthcare affordable, transparent and high quality again by providing expanded benefits at an affordable price, lowering premiums by up to 20%. We're building the health insurance we've always wanted for ourselves, with a high-tech, mobile-first experience focused on helping people live better, healthier lives.

Read More

FUTURE OF HEALTHCARE

Kubat HealthCare acquires Hilltop Drugs Etc

Kubat Healthcare | May 10, 2022

Kubat HealthCare, a leading health care service provider, announces today the acquisition of Hilltop Drugs Etc located at 108 W 11th St in Neligh, Nebraska 68756. Founded in October 2008 by co-founder and current Pharmacist-In-Charge, Jami Schmidt, Hilltop Drugs Etc quickly became a community staple providing personalized pharmacy and healthcare services. In 2019, Jami Schmidt and her business partner sold to Mark Vogt. "When I started Hilltop Drugs Etc in 2008, I wanted to provide the community with exceptional pharmacy solutions," said Jami Schmidt, who will remain as the Pharmacist-In-Charge, "I am thrilled that by joining with Kubat HealthCare, not only will our community continue to have pharmacy needs met, but we will now be able to offer additional health care services that have not been made available until now." By joining the Kubat HealthCare family, Neligh and surrounding communities will benefit from the access to respiratory care, specialized compounded medications, infusion, and home medical equipment solutions through their other locations in Nebraska. Hilltop Drugs Etc will continue to offer home delivery and mailing of patient's prescriptions, RediMedi compliance packaging, vaccinations, and assistance with enrolling in Medicare Part D prescription insurance plans. "The team at Hilltop Drugs is exceptional. While the name will change in the coming months, we are ecstatic to have Jami Schmidt and the team continue to provide exceptional service to the community." Tony Schmid, Vice President of Pharmacy Operations at Kubat HealthCare At Kubat HealthCare, their growth initiative has been focused on entering communities that have been previously underserved by their healthcare options. "Through our network, our team members are able to provide additional healthcare services to communities throughout the Midwest" said Bret Cain, COO of Kubat HealthCare, "And as we continue to grow, it reassures me that we are creating a beneficial healthcare network of service offerings to deserving communities."

Read More

DIGITAL HEALTHCARE

Walmart and Health at Scale Launch Customized Provider Recommendations for Plan Participants

Health at Scale | February 01, 2022

Health at Scale today announced a collaboration with Walmart to provide personalized provider recommendations to Walmart associates and their families who work in locations where Health at Scale is offered and are enrolled in the company's health plan. This technology will be incorporated into Walmart's health plan administrator's search engine and virtual care referrals for associates in select geographies, making it easier for plan participants to find providers that match to their unique health needs and care history. Through this initiative, Walmart and Health at Scale will establish a more personalized healthcare experience that focuses on the needs of each individual in the moment and leverages industry-leading machine intelligence to identify providers who have successfully treated patients with similar characteristics and care needs. "Finding the right provider is one of the most important health decisions a patient makes. It is also one of the hardest. What we really need to optimize is the patient-provider match. We're delighted to work with Walmart as the leader in employer health and benefits innovation and provide Walmart associates and their families in certain locations with smart, hyper-personalized provider matches that reflect a deep understanding and respect for their individual health needs." Health at Scale CEOZeeshan Syed Health at Scale's Precision Navigation™goes beyond non-personalized process-based star ratings, reputation rankings, and volume-based metrics and instead uses industry-leading AI and machine learning to model variations in provider outcomes across thousands of health factors. The service covers 25 different specialties as well as 34 procedures and imaging. "Customizing services and treatments to individual needs is the next frontier in healthcare and is a major part of Walmart's commitmentto helping associates and their family members find great doctors who consistently deliver the best value and quality care in their community," saidLisa Woods, VP, Walmart US Benefits. "We are excited to launch this collaboration with Health at Scale and are eager to see the impact that another innovative benefit like this will have on associates' healthcare experience and outcomes." About Health at Scale Health at Scale is a healthcare machine intelligence company that uses proprietary advances in artificial intelligence and machine learning to match individuals managed by insurers, employers and providers to the next best action in real-time and when needed most: whether it's the ideal choice of treatment, an early intervention, or the right provider. Founded by machine learning and clinical faculty fromMIT,Harvard,Stanford, and theUniversity of Michigan, the company's mission is to bring precision delivery to healthcare, learning from thousands of health variables from over a hundred million lives to generate personalized and precise insights for individual patients. Health at Scale's machine intelligence is deployed at scale in real operational settings -- including with some of the largest healthcare organizations in the country, driving better health outcomes and affordability for its customers. The company's software solutions service a broad range of use cases: provider navigation and network design, early targeted prediction and prevention of adverse outcomes, optimized treatment planning; and fraud, waste, and abuse prevention.

Read More

Spotlight

Healthcare’s "new front door" is the first stop on a consumer’s care journey. Banging this door down means vying for a different kind of consumer relationship. This relationship starts well before the consumer’s initial primary care or doctor visit. It begins with the tools that support consumers’ decision-making on whether and where to seek care. For this series, we take this “new front door” definition a step further and consider the strategic control and care delivery pieces connected right after someone steps through this door. This stage is what foreshadows the dynamics the new doors will drive in influencing consumer care patterns.

Resources